当前位置: 首页 > 期刊 > 《中国当代医药》 > 202025
编号:13810592
阿帕替尼与依托泊苷治疗复发难治小细胞肺癌的效果比较(5)
http://www.100md.com 2020年9月5日 《中国当代医药》 202025
     [15]Yan X,Wang Q,Wang H,et al.Apatinib as maintenance therapy in extensive-stage small-cell lung cancer:results from a single-center retrospective study[J].J Cancer Res Clin Oncol,2019,145(1):235-240.

    [16]Molina R,Augé JM,Bosch X,et al.Usefulness of serum tumor markers,including progastrin-releasing peptide,in patients with lung cancer:correlation with histology[J].Tumour Biol,2009,30(3):121-129.

    [17]Huang Z,Xu D,Zhang F,et al.Pro-gastrin-releasing peptide and neuron-specific enolase:useful predictors of response to chemotherapy and survival in patients with small cell lung cancer[J].Clin Transl Oncol,2016,18(10):1019-1025.

    [18]Wojcik E,Kulpa JK.Pro-gastrin-releasing peptide(Pro-GRP)as a biomarker in small-cell lung cancer diagnosis monitoring and evaluation of treatment response[J].Lung Cancer(Auckl),2017,8:231-240.

    [19]Petrovic M,Bukumiric Z,Zdravkovic V,et al.The prognostic significance of the circulating neuroendocrine markers chromogranin A,progastrin-releasing peptide and neuron-specific enolase in patients with small-cell lung cancer[J].J Med Oncol,2014,31(2):823.

    (收稿日期:2019-05-15), 百拇医药(石玲 王志 左宏波)
上一页1 2 3 4 5